425: BioNTech to Acquire CureVac in All-Stock Exchange Offer, Expanding mRNA Capabilities

BioNTech SE has announced a definitive agreement to acquire CureVac N.V. through a public exchange offer, leading to CureVac's delisting and full integration into BioNTech's operations.

Summary

• BioNTech SE will acquire CureVac N.V. through a public exchange offer, where CureVac shareholders will exchange their ordinary shares for BioNTech American Depositary Shares (ADSs).
• The exchange ratio for CureVac shares will be calculated by dividing $5.4641 by the volume-weighted average price (VWAP) of BioNTech ADSs over a 10-day period, with a floor of 0.06476 BioNTech ADSs per CureVac share (if BioNTech ADS VWAP is less than or equal to $84.37) and a cap of 0.04318 BioNTech ADSs per CureVac share (if BioNTech ADS VWAP is greater than or equal to $126.55).
• The offer is contingent on a minimum tender condition of at least 80% of CureVac's issued and outstanding shares, which BioNTech may reduce to 75% under specific circumstances.
• Following the exchange offer, CureVac will undergo a corporate reorganization, including a Dutch legal downstream merger, a share sale, and a cancellation transaction, which will result in CureVac becoming a wholly-owned subsidiary of BioNTech and its shares being delisted from Nasdaq.
• The transaction is expected to be completed by March 12, 2026, though this date is subject to potential extensions, particularly concerning antitrust approvals.
• Certain CureVac shareholders have entered into tender and support agreements, committing to tender their shares in the offer and vote in favor of the transaction.

Sentiment

Score: 7

Explanation: The document outlines a clear path for BioNTech's acquisition of CureVac, indicating strategic expansion and a definitive agreement between the parties. While standard risks and termination clauses are present, the overall sentiment is positive due to the progression of the transaction.

Positives

• BioNTech is strategically expanding its capabilities and market position by acquiring CureVac, a key player in mRNA technology.
• CureVac shareholders will receive BioNTech ADSs, providing them with continued exposure to the biopharmaceutical sector through a larger, publicly traded entity.
• The agreement includes a structured post-offer reorganization plan, ensuring a clear path for CureVac's integration into BioNTech and the cessation of its public reporting obligations.
• Provisions for the treatment of CureVac's outstanding equity awards (virtual share awards, performance stock units, restricted stock units, and options) are outlined, providing clarity for beneficiaries.
• The support agreements from certain CureVac shareholders indicate a level of confidence and commitment to the transaction from significant stakeholders.

Negatives

• CureVac will cease to be a publicly traded company, and its shares will be delisted from Nasdaq, ending its independent presence in the public market.
• The variable exchange ratio, tied to BioNTech's ADS VWAP, introduces uncertainty regarding the precise number of BioNTech ADSs CureVac shareholders will receive until closer to the offer's expiration.
• The transaction is subject to various conditions, including a minimum tender threshold and regulatory approvals, which could lead to delays or potential termination.
• CureVac is obligated to pay a termination fee of $43,750,000 to BioNTech under specified circumstances, such as entering into a superior proposal or a willful breach of non-solicitation obligations.
• BioNTech is obligated to pay a termination fee of $62,500,000 to CureVac if the agreement is terminated due to failure to obtain antitrust approvals.

Risks

• Uncertainties regarding the timing of the exchange offer and the subsequent corporate reorganization of CureVac.
• Risk that a sufficient number of CureVac shareholders may not tender their shares in the exchange offer, potentially preventing the Minimum Condition from being met.
• The possibility of competing offers or alternative acquisition proposals emerging for CureVac.
• Risk that various conditions to the consummation of the exchange offer and the transactions contemplated by the Purchase Agreement may not be satisfied or waived.
• The possibility of a termination of the Purchase Agreement under various specified circumstances.
• Inability to obtain necessary antitrust and other regulatory approvals, or to obtain them on acceptable terms or within expected timing.
• Potential disruption to BioNTech's and/or CureVac's business operations, including relationships with employees, business partners, or governmental entities, due to the announcement and pendency of the transactions.
• Risk that the exchange offer or the other transactions contemplated by the Purchase Agreement may be more expensive to complete than anticipated.
• Risk of litigation in connection with the exchange offer or the other transactions, which may result in significant costs of defense, indemnification, and liability.
• Diversion of management's attention from ongoing business operations and opportunities as a result of the exchange offer and related transactions.
• General industry conditions and competition, which could impact the value or success of the combined entity.
• General political, economic, and business conditions, including fluctuations in interest rates, inflation, tariffs, and currency exchange rates, as well as ongoing geopolitical conflicts (Russia-Ukraine and Middle East).
• Impact of regulatory developments and changes in the United States, Europe, and other countries, including those related to tax matters.
• Impact of pharmaceutical industry regulation and healthcare legislation in various jurisdictions.
• Particular prescribing preferences of physicians and patients, which could affect product adoption.
• Challenges and uncertainties inherent in new product development, including clinical trial outcomes and regulatory pathways.
• Ability to obtain or maintain proprietary intellectual property protection, which is crucial in the biopharmaceutical sector.
• Safety, quality, data integrity, or manufacturing issues related to products.
• Potential or actual data security and data privacy breaches.
• Ongoing litigation between CureVac and BioNTech, including any potential dismissal or mutually agreed settlement thereof, which could impact the transaction.

Future Outlook

The document outlines the future integration of CureVac into BioNTech's operations, including the delisting of CureVac shares and the cessation of its public reporting obligations. It details the continued operation of CureVac S.E.'s biopharmaceutical R&D and CureVac Manufacturing GmbH's manufacturing business post-acquisition. The parties intend for the transaction to qualify as one or more reorganizations for U.S. federal income tax purposes.

Management Comments

• The management board of the Company (CureVac) and the supervisory board of the Company have determined that, on the terms and subject to the conditions set forth in this Agreement, this Agreement and the Signing Transactions, are in the best interest of the Company and the sustainable success of its business, having considered the interest of its shareholders, employees and other relevant stakeholders.
• The management board and the supervisory board of Buyer (BioNTech) have each unanimously determined that, on the terms and subject to the conditions set forth in this Agreement, this Agreement and the Transactions are in the best interests of Buyer and all of its stakeholders.

Industry Context

This acquisition represents a strategic move by BioNTech, a leading biopharmaceutical company, to integrate CureVac, another player in the mRNA technology space. This consolidation could enhance BioNTech's research and development capabilities, potentially strengthening its position in the competitive biopharmaceutical industry, particularly in the mRNA therapeutic and vaccine development sector. It reflects a trend of larger pharmaceutical companies acquiring smaller, innovative biotech firms to expand pipelines and technological platforms.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing litigation between CureVac and BioNTech is noted as a risk factor, with the possibility of potential dismissal or mutually agreed settlement.
• The risk of litigation in connection with the exchange offer or other transactions is highlighted, which could result in significant costs of defense, indemnification, and liability.

Related Party Transactions

• Certain shareholders of CureVac, specifically dievini and Kreditanstalt für Wiederaufbau (Major Shareholders), have entered into tender and support agreements with BioNTech, committing to tender their shares and vote in favor of the transaction.
• The Company Prior VSOP Awards involve 'Contributing Shareholders' (dievini and certain other pre-IPO shareholders) who have agreed to transfer Company Shares to settle these awards, which constitutes a related party arrangement.

Stakeholder Impact

• **CureVac Shareholders**: Will exchange their shares for BioNTech ADSs, losing direct equity in CureVac but gaining exposure to BioNTech's larger operations and future prospects. Minority shareholders will receive the same consideration through the post-offer reorganization.
• **BioNTech Shareholders**: Will experience dilution due to the issuance of new ADSs to acquire CureVac shares.
• **CureVac Employees**: Continuing employees will receive at least the same base salary and target annual bonus opportunity for one year post-closing. They will also receive substantially similar employee benefits (excluding severance, equity, change in control, retiree medical, and defined benefit retirement benefits) and credit for prior service for eligibility, vesting, and vacation benefits.
• **CureVac Management/Directors**: The management and supervisory boards will be reconstituted with BioNTech designees. Existing directors and officers will be indemnified and covered by tail D&O insurance for six years post-transaction.
• **Customers, Suppliers, and Business Partners**: The announcement and pendency of the transactions carry a risk of disruption to existing relationships. BioNTech commits to using reasonable best efforts to preserve material business relationships post-closing.

Next Steps

• BioNTech to commence the exchange offer promptly after the Form F-4 becomes effective and the EU Prospectus is approved by BaFin (and UK Prospectus Document by FCA, if required).
• CureVac to hold an Extraordinary General Meeting (EGM) as promptly as practicable, but within five weeks of the Offer Commencement Date, to approve corporate reorganization steps and board appointments.
• BioNTech to file a registration statement on Form F-4 and a Tender Offer Statement on Schedule TO with the SEC.
• CureVac to file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC.
• BioNTech and CureVac to use reasonable best efforts to obtain required antitrust and other regulatory approvals.
• Following the expiration of the Subsequent Offering Period, BioNTech will effectuate a corporate reorganization of CureVac, including a Dutch legal downstream merger, share sale, and cancellation.
• CureVac shares are to be delisted from Nasdaq and deregistered under the Securities Exchange Act of 1934.
• BioNTech to cause the Buyer ADSs to be issued in the Offer to be approved for listing on Nasdaq.
• BioNTech will cause CureVac's management and supervisory boards to be reconstituted with BioNTech designees and independent directors upon closing.
• CureVac will use reasonable best efforts to amend the terms of its outstanding virtual share awards (Company Prior VSOP Awards) to allow for settlement.
• CureVac will take actions necessary to terminate any Company Plan intended to include a Code section 401(k) arrangement, if requested by Buyer.

Key Dates

Recommendation

Keywords

BioNTech, CureVac, acquisition, exchange offer, merger, biopharmaceutical, mRNA, biotechnology, SEC filing, corporate reorganization, delisting, Nasdaq, American Depositary Shares, ADSs, volume-weighted average price, VWAP, minimum tender condition, regulatory approvals, antitrust, shareholder approval, termination fee, corporate governance, equity awards